1 Answers
Gliflozins are a class of drugs in the treatment of type 2 diabetes. They act by inhibiting sodium/glucose cotransporter 2 , and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria. The mechanism of action is insulin independent.
Three drugs have been accepted by the Food and Drug Administration in the United States; dapagliflozin, canagliflozin and empagliflozin. Canagliflozin was the first SGLT-2 inhibitor that was approved by the FDA, being accepted in March 2013. Dapagliflozin and empagliflozin were accepted in 2014.
4 views
Answered